Introduction
Hypertrophic cardiomyopathy (HCM) is a heart disorder characterized by left-ventricular hypertrophy (thickness ≥15 mm) unexplained by secondary causes, and non-dilated left ventricle with preserved or increased ejection fraction. It is an important cause of sudden cardiac death and its prevalence has been estimated at ~1/500 individuals in the adult population [1] . HCM is considered a disease of the cardiac sarcomere mainly caused by pathogenic variants in over 10 loci, with MYBPC3, MYH7 and TNNT2 accounting for ≈50% of the HCM families and encoding, respectively, the cardiac myosin-binding protein C, the β-myosin heavy chain, and the cardiac troponin T [2] . Other inheritable causes of the disease include pathogenic variants in genes coding for proteins involved in calcium handling and for proteins of the Z-disk [3] . Most of the pathogenic variants found in HCM genes are missense and unique or private within families [2] . These alterations are believed to have a dominant negative effect, acting as a "poison polypeptide" on sarcomere function [4] . The only exception is MYBPC3, in which about two-thirds of pathogenic variants are truncating and haploinsufficiency is postulated as a mechanism for disease pathogenesis [5] . To date, at least 12 different truncating MYBPC3 pathogenic changes have been reported as founder variants in populations from Finland, France, Japan, Iceland, Italy, Spain and The Netherlands [5] [6] [7] [8] .
In most adolescents and adults, HCM is inherited as an autosomal dominant trait with a clinical outcome characterized by incomplete penetrance and variable expression. The disease phenotype can indeed be modulated by environmental factors, by the genetic context (including polymorphisms of the renin-angiotensin system [9] ), and by the occurrence of the causal pathogenic variant/s in homozygosity, compound heterozygosity or double heterozygosity [10] . About this, Janin et al. recently reported two unrelated kindred with homozygous truncating variants in the cysteine and glycine-rich protein 3 (CSRP3) gene encoding the Z-disk muscle LIM protein (MLP) [11] .
It is likely that HCM individuals are under diagnosed [12] , especially in countries where availability of genetic testing based on Next Generation Sequencing (NGS) is limited. Considering the prevalence of HCM, the estimate of the number of HCM patients in Poland is approximately 78,000. Until now, only single reports describing genetic causes of HCM in polish patients have been reported [13] [14] [15] . Therefore, the aim of the current study was to assess the genetic background of HCM in a cohort of patients from the south-eastern part of Poland analyzed by NGS panel including 404 genes known to harbour alterations affecting cardiovascular functioning. Thanks to this approach, we could identify a MYBPC3 truncating alteration that could represent a novel polish founder MYBPC3 pathogenic variant. Also, we detected a novel patient with homozygous CSRP3 variant, increasing to three the number of HCM cases with null homozygous alterations in this gene.
Patients and Methods

Patients.
Twenty-nine unrelated patients were selected from those attending an outpatient service dedicated to the diagnosis and management of HCM at the Institute of Cardiology, John Paul II Hospital (Cracow, Poland). The patients underwent clinical history registration, physical examination, electrocardiography (ECG), echocardiography, cardiopulmonary exercise test coupled with ambulatory ECG monitoring and cardiac magnetic resonance (CMRI). Diagnostic criteria for HCM was defined in adults by a maximal left ventricular wall thickness ≥15 mm on echocardiography, or ≥13 mm in relatives, in the absence of loading conditions [16] . Family history of sudden cardiac death (SCD), syncope episodes and the presence of non-sustained ventricular tachycardia (NSVT) were defined as described by O'Mahony et al. [17] . Electrocardiographic changes that were considered of clinical significance included abnormal Q waves (0.04 s or 25% depth of an R-wave), LVH (voltage criteria), and marked repolarization changes (e.g. T-wave inversion in at least 2 leads). Familial HCM cases were defined if at least one additional affected family member with HCM, or one case of sudden cardiac death was present in the pedigree. When available, the relatives of index cases were recruited for genetic testing. All patients gave informed consent for the DNA analyses, which was approved by local ethic committees in accordance with the principles of the Declaration of Helsinki.
Genetic analyses. Genomic DNA from peripheral blood was tested by NGS with the Ion
AmpliSeq™ Cardiovascular Research Panel (ThermoFisher, Carlsbad, CA, USA), including the 16 "core HCM genes" defined by the American College of Medical Genetics and Genomics (ACMG) [18] , as well as other 388 genes known to harbour alterations affecting cardiovascular functioning (Table S1 ). The Ion Chef System (ThermoFisher) was employed for the automated library and template preparation, and for chip loading. Sequencing reactions were carried out on the Ion S5 XL System (ThermoFisher). Sequencing reads were aligned on the GRCh37/hg19 reference sequence by the Torrent Suite Software v.5.4.0 (ThermoFisher). For every patient, the panel coverage as well as the mean and median read depth reached for each of 404 genes is given in Table S1 . The mapped Table S2 ) and classified into the five ACMG/AMP 2015 guidelines categories [19] modelled by a Bayesian framework as previously described [20] . 
Statistical assessment of genotype-phenotype correlations.
All statistical analyses were performed using SPSS (statistical software package version 20.0). For each patient, the clinical data and molecular data were tabulated ( Figure 1 ). Phenotype data were presented as continuous variables obtained from clinical data and instrumental measurements and were summarized using means and standard deviations. Mean values of age at diagnosis, maximal wall thickness and left ventricular mass were compared using the Student's t-test for independent data between subgroups of patients with different genotypes. Also, association between the gender, the genotype of two polymorphisms in genes of the renin-angiotensin system and clinical features were tested. HCM penetrance, according to age at diagnosis, was analyzed by the Kaplan-Meier method and differences between cumulative hazard were evaluated with the log-rank test. Due to the relatively low number of patients, no adjustments was planned for multiple testing; the analysis is therefore exploratory and results to be considered as hypotheses-generating.
Results and Discussion
In total, 12 among 29 patients (41%) were found to carry at least one pathogenetic (P), likely pathogenetic (LP) or VUS-favouring pathogenic (VUS-3B) alteration of "core HCM genes", as classified by ACMG/AMP_2015 and/or ClinVar database ( Table 1 and Figure 1 ). Most of the changes were identified in MYBPC3, MYH7 and TNNT2 genes. The genotype of rs5186 and rs699 polymorphisms, mapping respectively in the angiotensin receptor type 1 (AGTR1) and angiotensinogen (AGT) genes, belonging to the renin-angiotensin system (RAS), were also recorded ( Figure 1 ). Indeed, some studies have shown that rs5186 and rs699 may influence clinical phenotype of HCM [22] since the RAS regulates cardiac function, blood pressure, and electrolyte homeostasis [23] . However, in the present cohort, no statistically significant correlation with the disease expression was found.
The identified mutational spectrum included 10 distinct substitutions: six missense, three nonsense and one intronic change. Most of the missense variants were sarcomeric and, among them, three mapped in MYH7, two in MYBPC3 and a one in TNNT2. On the other hand, two of the nonsense alterations were found in MYBPC3 and one in CSRP3. The GnomAD allele frequency of all the sarcomeric alterations was smaller than 0.01%, that is the MAF threshold suggested for HCM pathogenic variants [24] .
A single variant was found to occur in more than one patient ( Figure S1A ). The To investigate whether carriers of the MYBPC3 c.2541C>G variant could share a common ancestor, we performed a markers analysis. A haplotype, spanning about 5Mb, was found to segregate with the c.2541G variant allele in the family of patient 22. The alleles of the c.2541G-haplotype were also present in all the MYBPC3 c.2541C>G carriers ( Table 2) , even if we could not reconstruct their phase. This finding supports the hypothesis that the MYBPC3 c.2541C>G could have a founder role in the Polish population. In support of this hypothesis, the MYBPC3 c.2541C>G was recently found in another Polish HCM patient, not related to any of the here reported cases [25] .
Case 58 was found to carry the truncating CSRP3 c.364C>T (p.Arg122Ter) variant in homozygosity ( Figure S1B The CSRP3 c.364C>T (p.Arg122Ter) is not a common variant since absent in GnomAD-Genomes and in GnomAD-Exomes-European databases. In total, only three CSRP3 c.364C>T alleles are listed GnomAD-Exomes (i.e. two in African and one in South Asian populations), but never in a homozygous state. It was not previously described in literature, but it is listed as likely pathogenic in ClinVar database because of the following evidences: (i) it is a rare variant; (ii) it is predicted to cause loss of protein function either by protein truncation or nonsense-mediated mRNA decay; (iii) CSRP3 null mice develop cardiomyopathy and heart failure due to a disrupted cardiomyocyte architecture [26] ; (iv) myocardial biopsies of a HCM patient with a heterozygous CSRP3 missense variant showed myocyte disarray and a reduced level of MPL protein, suggesting that cardiomyopathy may stem from CSRP3 haploinsufficiency [27] . To date, 24 cases carrying a CSRP3 alteration were reported in literature and/or included in the ClinVar database: 18 were HCM while 6 were cases affected by dilated cardiomyopathy. Among the HCM patients, 9 carried a heterozygous CSRP3 change (including 7 aminoacid substitutions and 2 truncating variants), 2 cases were heterozygous but also carried a second variant in another gene, while 2 patients harboured a truncating alteration in homozygosity [11] (Table 3) . Therefore, the here described patient 58 is the third CSRP3 human knockout case so far reported. Our finding strengthen the assumption that, at least several CSRP3 variants, do lead to hypertrophic cardiomyopathy with an autosomal recessive inheritance [11] rather than with an autosomal dominant transmission as recorded in the Online Mendelian Inheritance in Man (OMIM) database (MIM:*600824). The mouse model knock-in for CSRP3 pathogenic variants, also corroborates the hypothesis of autosomal recessive inheritance of the cardiac disease and recalls the findings displayed by patient 58 and his son [28] . Indeed, the heterozygous mice for CSRP3 pathogenic variants do not display an overt cardiac phenotype (except for an increase of anterior wall thickness), while the homozygous mutated mouse shows a clear cardiomyopathy phenotype [28] .
The "non-core HCM genes" resulting mutated in the present HCM cohort were GYG1, GUSB, autosomal recessive alterations respectively associated to PMM2-Carbohydrate-deficient glycoprotein syndrome type I, SCO2-Cardioencephalomyopathy due to cytochrome c oxidase deficiency 1, GUSB-Mucopolysaccharidosis type VII and GYG1-glycogenin 1 deficiency (Table 4 ).
The GYG1, GUSB, PMM2 and SCO2 variants were prioritized by TGex software since related to the cardiomyopathy phenotype: the GYG1 c.304G>C, found in patient 218, has previously been described in homozygosity in cases affected by severe cardiomyopathy without skeletal muscle weakness [29]; the GUSB and PMM2 genes are responsible for genetic disorders associated with hypertrophic cardiomyopathy [30] ; the SCO2 c.418G>A variant have been previously reported by the name of "c.1541G>A" in homozygosity or in compound heterozygosity in individuals with SCO2-related clinical features including HCM [31, 32] . Therefore, these results can be considered "secondary findings" for which we cannot exclude a possible hypomorphic impact over the patients' phenotype. Also, the SCO2 p.Glu140Lys was previously associated to autosomal dominant high-grade myopia [33] . In the present patient, presenting low myopia of -2.00 dioptres in both eyes, the SCO2 c.418G>A exhibited with reduced penetrance.
In conclusion, this report expands the mutational spectrum and the inheritance pattern of hypertrophic cardiomyopathy. The ultra-rare MYBPC3 c.2541C>G (p.Tyr847Ter) change, found in a total of 9 cases (of which 4 index patients), while absent in databases from large-scale sequencing projects, acts for a variant hotspot in the present polish cohort and correlates with a lower age at HCM diagnosis. This findings, if confirmed on a wider population of the same ethnic origin, will increase the number of truncating founder MYBPC3 alterations.
The identification of a novel homozygous null CSRP3 variant leading to hypertrophic cardiomyopathy suggests that the autosomal recessive inheritance pattern could be more frequent in HCM than what has been so far reported. In heterozygosity, the null CSRP3 allele seems to correlate only with a mild thickening of the intraventricular septum. 
